Peroxisomes are small structures inside cells that help remove harmful substances but also break down fats. In animal studies, researchers disrupted these structures and found it damaged the cells that produce insulin (called beta or β cells) in three ways: promoted oxidative stress (a kind of cellular wear and tear), altered the chemical structure of the hormone insulin, and reduced signs that the cells were fully mature and functioning normally. Strangely, the animals released more insulin in response to sugar, yet their bodies were less able to keep blood sugar under control.

The study, published in JCI Insight, helps explain how problems inside cells may drive the loss of healthy insulin production seen in diabetes.

A newly developed radiotheranostic pair, ⁶⁸Ga/¹⁷⁷Lu-NYM096,  can identify tumors and effectively deliver targeted radiotherapy to patients with metastatic clear cell renal cell carcinoma (ccRCC). Using a small molecule compound, the new approach helps to mitigate toxicity issues common with treatment, offering a safe and feasible strategy for those with end-stage disease. This research was published in the September issue of The Journal of Nuclear Medicine.

Scientists from Gladstone Institutes, UC San Francisco, and Stanford University, in collaboration with Biohub, have unveiled a massive, high-resolution functional map of human immune cells that promises to transform our understanding of how genetics control health and disease. Published in the journal Cell, the study represents a landmark achievement in immunology and genomics. By systematically stress-testing genes across the genome in 22 million human immune cells, scientists moved beyond mere DNA sequencing to decode the dynamic circuits that govern how these genes actually work in the context of health and disease.

JMIR Publications Welcomes Prof Sebastian Spethmann as Editor in Chief of JMIR Cardio

Nocturnal enuresis (NE) in school-age children is more than a nighttime inconvenience: when persistent, it can affect self-esteem, sleep, family life and social functioning.

August 31 – September 3 | Riyadh

Dr. Alex Zhavoronkov, Founder and CEO of Insilico Medicine, has been invited to attend LEAP 2026 on September 2.

September 1 | Shenzhen

Dr. Feng Ren, Co-CEO and Chief Scientific Officer of Insilico Medicine, will attend the UBS China A-Share Conference 2026 in Shenzhen on September 1, participating in a panel discussion and delivering a speech.

September 2 | Suzhou

Dr. Feng Ren, Co-CEO and CSO of Insilico Medicine, will attend the 6th SCS Healthcare Conference in Suzhou on September 2 to deliver a keynote speech.

September 6 | Xiamen

Dr. Feng Ren, Co-CEO and CSO of Insilico Medicine, will attend the 2026 Xiamen Tech Innovation and Securities Industry Development Conference on September 6